HIV VACCINES AND MICROBICIDES RESOURCE TRACKING WORKING GROUP
The US remains main contributor, call for broader global partnering
The US remained the largest public-sector investor overall, spending a total of US$925 million in 2012—70 percent of the total investment in HIV prevention R&D. European public-sector investment totaled US$86 million, other governments invested US$69 million, philanthropic organizations invested US$203 million and the commercial sector invested US$34 million.
A more diverse global cadre of funders, both involved in and dedicated to advancing HIV prevention R&D, would better utilize global resources and represent a powerful force in the effort to bring down new infections. An expanded and more diversified investment base could draw on nontraditional sources, such as emerging economies and countries hosting clinical and other HIV prevention research, along with recommitted member states of the Organization for Economic Co-operation and Development (OECD), whose support for HIV prevention R&D has waned over the past several years.
The foundation for such efforts is in place. The HIV prevention field has worked to catalyze innovative partnerships across the public, private, philanthropic and academic sectors in order to capitalize on available resources and advance promising pipeline candidates. Still, greater efficiency and clarity in directing funding toward the most effective programs, and assuring that such investments are complementary rather than duplicative, would go a good distance toward optimizing investments across all areas of research. Always a desirable state of affairs, such participation, partnering, and shared processes for managing HIV prevention R&D must now become even more rigorous as economic and budgetary pressures become features of the global health research landscape that are unlikely to change in the near future.